Novo Nordisk CEO Favors Trump Plan to Limit Rebates

Novo Nordisk's CEO discusses the company's optimistic growth outlook despite US pricing pressures. The conversation covers the impact of US rebate policy changes, international growth, and insulin pricing. The CEO highlights efforts to improve patient access and affordability, especially in the US, while addressing concerns about rising insulin prices.

What growth did Novo Nordisk experience in the US tier one category in 2018?

• 20%

• 18%

• 15%

• 10%

How does the CEO of Novo Nordisk view the Trump administration's proposal on rebates?

• As irrelevant to their business

• As a temporary measure

• As a positive step towards patient affordability

• As a threat to the company's profits

Which region did not see growth for Novo Nordisk in 2018?

• Latin America

• Japan

• Middle East

• China

What initiative has Novo Nordisk taken to help Americans who cannot afford insulin?

• Increased insulin prices

• Partnered with other companies to increase prices

• Stopped selling insulin in the US

• Provided free insulin to over 50,000 Americans

What percentage of rebates did Novo Nordisk give to middlemen in 2018?

• 50%

• 60%

• 70%

• 68%